Observing Huntington's disease: The European Huntington's disease network's registry

PLoS Currents

Volumn , Issue SEP, 2010, Pages

  Orth, Michael ^a   Handley, Olivia J ^b   Schwenke, Carsten ^c   Dunnett, Stephen B ^d   Craufurd, David ^e   Ho, Aileen K ^f   Wild, Edward ^b,h   Tabrizi, Sarah J ^b   Landwehrmeyer, G Bernhard ^g  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Statistical Institute   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF READING   (United Kingdom)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871183930     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1184     Document Type: Article

References (29)

1. Huntington G. On chorea. Med Surg Reporter 1872;26:320-1.
2. Walker FO. Huntington's disease. Lancet 2007;369:218-28.
3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
4. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007;30:575-621.
5. Handley OJ, Naji JJ, Dunnett SB, Rosser AE. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 2006;110:73-88.
6. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-42.
7. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-5.
8. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
10. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36® Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.
11. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, ed. Measuring Mental Health Needs. 2nd ed. London: Gaskell; 2001.
12. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist 1989;29:798-803.
13. Beck JC, Beiswanger CM, John EM, Satariano E, West D. Successful transformation of cryopreserved lymphocytes: a resource for epidemiological studies. Cancer Epidemiol Biomarkers Prev 2001;10:551-4.
14. Bernacki SH, Stankovic AK, Williams LO, et al. Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. J Mol Diagn 2003;5:227-30.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
16. Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes 1993;7:235-9.
17. Riess O, Noerremoelle A, Soerensen SA, Epplen JT. Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease. Hum Mol Genet 1993;2:637.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
19. Quarrell O, Brewer HM, Squitieri F, Barker RA, Nance M, Landwehrmeyer GB. Juvenile Huntington's Disease. Oxford: Oxford University Press; 2009.
20. Penney JB, Jr., Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-92.
21. Harper PS. The epidemiology of Huntington's disease. In: Bates G, Harper PS, Jones L, eds. Huntington's disease. Oxford: Oxford University Press; 2002:159-97.
22. Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004;101:3498-503. Epub 2004 Mar 1.
23. Seldin MF, Shigeta R, Villoslada P, et al. European population substructure: clustering of northern and southern populations. PLoS Genet 2006;2:e143. Epub 2006 Jul 25.
24. Ranen NG, Stine OC, Abbott MH, et al. Anticipation and instability of IT-15 (CAG)n repeats in parentoffspring pairs with Huntington disease. Am J Hum Genet 1995;57:593-602.
25. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-10.
26. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-20.
27. Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry 2008;79:1088-92. Epub 2008 Jan 10.
28. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24:98-104. Epub 2009 Feb 7.
29. Hobart J, Cano S, Zajicek J, Thompson A. Rating Scales as outcome measures for clinical trials in neurology: problems, solution, and recommendations. Lancet Neurology 2007;6:1094-105.